Research & Development Solution Center

71. Competing In The Rare Disease Space 10/31/2013

    Competition has picked up in the rare disease market which is now worth about $10 billion. Russell Basser, senior VP of global clinical research and development at CSL Behring reflects, “The rare disease space is becoming so crowded. We all have to be that much smarter about how we do business and it puts more pressure on drug development.”

72. Guidelines For Launching A Successful Biotech Company 10/31/2013

    There are various ways a young biotech company can improve their chances of success by having a well-defined commercialization strategy that is efficient and flexible, balancing commercialization progress with innovation and leveraging partnerships and collaboration with industry experts.

73. How To Strengthen Biotech's Pipeline? Partner With Academia 10/3/2013

    In 2013, many of the advancements in biotech didn’t come from biotech companies, they came from academia. Integrating academic institutions with the research and development pipeline with access to their facilities and research potential could are of major importance.

74. Access To Big Data Accelerates Discovery And Cuts Drug Development Costs 10/3/2013

    Today’s medicinal chemists and molecular and cell biologists often rely on sophisticated computer-based resources to assess a therapeutic area and to more efficiently interpret and analyze large volumes of information. To help control costs and move as quickly as possible through all aspects of development and clinical trials, biotechs have sought outside help.

75. Do The Right Thing: GSK's Case For Data Transparency 10/2/2013

    GlaxoSmithKline’s head of science and innovation argues that the future progress of R&D industrywide depends on open but qualified sharing of all clinical-trials data.

76. The Importance Of Investment And R&D In The Health Of Life Sciences 8/29/2013

    The AIM IPO market has seen a number of significant listings recently in life sciences, especially for medical device and clinical services. For companies involved in drug discovery, the market remains challenging. But there are signs of interest in the drug discovery sector that the AIM market demonstrates a willingness to invest in businesses carrying out quality R&D, albeit in this case counter-balanced by a novel clinical services business.

77. Israel Drives Middle East Biotech Start-ups 7/31/2013

    Israel has been called, accurately, a nation of start-ups. With its scientifically oriented population and entrepreneurial drive, the nation is driving Middle East biotech. Approximately 60 percent of Israel’s life sciences companies focus on medical devices, while about 35 percent focus on biopharmaceuticals. Typically, 40 to 60 biotech companies are founded each year.

78. Sanofi Pharma R&D, The Case For Change Was Not Hard To Make 7/31/2013

    Sanofi will be the most productive and profitable R&D operation in the biopharmaceutical industry in 2015. That’s the vision of Elias Zerhouni, M.D., the company’s president of global R&D, and Sanofi CEO Chris Viehbacher, who persuaded Zerhouni, the former NIH director, to leave the world of academia where he had built a reputation as an innovative, successful, and charismatic leader.

79. Ask The Board July 2013 7/9/2013

    What is the biggest mistake you have seen a c-level leader make?

80. J&J's Approach To Drug Discovery And Breakthrough Therapy 7/1/2013

    One year ago, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Its most current version includes a provision that allows sponsor companies to request their drug be designated as a “breakthrough therapy.” In February, Johnson & Johnson (J&J) became only the second company (behind Vertex Pharmaceuticals) to have a drug receive this designation.